Cited by 173Cardiac pacing and defibrillation studiesAtrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy

Open access
Saksena, Sanjeev, Prakash, Atul, Ziegler, Paul, Hummel, John D, Friedman, Paul, Plumb, Vance J, Wyse, D.George, Johnson, Eric +2 more·2002·Journal of the American College of Cardiology

Abstract

Objectives We compared the safety, tolerance and effectiveness of overdrive high right atrial (RA), dual-site RA and support (DDI or VDI) pacing (SP) in patients with symptomatic atrial fibrillation (AF) and bradycardias.Background Optimal pacing methods for AF prevention remain unclear.Methods Patients (n = 118) were randomized to each of three pacing modes in a crossover trial.Results Mode adherence was superior for dual-site RA (5.8 months) compared with SP (3.3 months; p < 0.001) and high RA pacing (4.7 months; p = 0.006). Adverse event-free survival improved with dual-site RA (p = 0.007 vs. SP) and was comparable to high RA (p = 0. 75). AF-free survival trended to improve with dual-site RA (hazard ratio [HR] 0.715, p = 0.07 vs. SP) but not high RA (HR = 0.71, p = 0.19) or when dual-site RA was compared with high RA (HR = 0.835, p = 0.175). Time-to-recurrence was longer in dual-site RA (1.77 months) compared with high RA (0.62 months, p < 0.09) or SP (0.44 months, p < 0.05). In antiarrhythmic drug-treated patients, dual-site RA reduced recurrence risk compared with SP (HR = 0.638, p = 0.011) and high RA (HR = 0.669, p = 0.06). In patients with < or =1 AF event/week, dual-site RA improved AF suppression (HR = 0.464, p = 0.004 vs. SP; HR = 0.623, p = 0.006 vs. high RA). Dual-site RA improved AF-free and mode survival (p < 0.03 vs. high RA, p < 0.001 vs. SP) and reduced asymptomatic AF (p < 0.01 vs. high RA).Conclusion Dual-site RA is safe and better tolerated than high RA and SP. In patients on antiarrhythmics, dual-site RA prolonged and high RA trended to prolong time-to-recurrent AF compared with SP. Dual-site RA provides superior symptomatic and asymptomatic AF prevention compared with high RA in patients with symptomatic AF frequency of < or =1/week.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0735-1097(02)02068-5

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Daubert, 1994, Atrial tachyarrhythmias associated with high degree interatrial conduction block, Eur J Card Pacing Electrophysiol, 1, 35
  2. Prakash, 2001, Dual-site atrial pacing for prevention of atrial fibrillation (DAPPAF) trial, PACE, 24, 553

Cited by

Sorted by citations

Authors
Saksena, S., Prakash, A., Ziegler, P., Hummel, J. D., Friedman, P., Plumb, V. J., Wyse, D. G., Johnson, E., Fitts, S., & Mehra, R.
Affiliations
  • Atlantic Health System (US)
  • Medtronic (United States) (US)
  • Mayo Clinic (US)
  • University of Alabama at Birmingham (US)
  • University of Calgary (CA)
  • The Stern Cardiovascular Foundation (US)
Corresponding author
Saksena, Sanjeev
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2002-09
Volume
40
Issue
6
Pages
1140-1150
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2150916657
Cited by
171
References
20
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 4 · 2013: 2 · 2012: 4
FWCI
15.44
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
atrial fibrillation suppression, overdrive pacing, antiarrhythmic drugs, atrial fibrillation recurrence, bradycardia, atrial fibrillation prevention, asymptomatic atrial fibrillation, crossover trial
MeSH terms
Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Bradycardia, Cardiac Pacing, Artificial, Combined Modality Therapy, Female, Heart Atria, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Cross-Over Studies, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review